Your browser is no longer supported. Please, upgrade your browser.
FATE Fate Therapeutics, Inc. daily Stock Chart
FATE [NASD]
Fate Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.57 Insider Own0.90% Shs Outstand75.89M Perf Week-2.62%
Market Cap2.99B Forward P/E- EPS next Y-1.96 Insider Trans179.81% Shs Float65.25M Perf Month6.88%
Income-111.90M PEG- EPS next Q-0.27 Inst Own89.50% Short Float16.85% Perf Quarter29.49%
Sales10.60M P/S281.78 EPS this Y-21.50% Inst Trans4.68% Short Ratio10.28 Perf Half Y60.64%
Book/sh2.89 P/B12.20 EPS next Y-20.40% ROA-38.40% Target Price38.81 Perf Year72.42%
Cash/sh2.40 P/C14.69 EPS next 5Y- ROE-52.10% 52W Range12.59 - 38.52 Perf YTD80.17%
Dividend- P/FCF- EPS past 5Y-2.60% ROI-41.10% 52W High-8.46% Beta1.77
Dividend %- Quick Ratio8.40 Sales past 5Y- Gross Margin- 52W Low180.06% ATR2.20
Employees178 Current Ratio8.40 Sales Q/Q-3.80% Oper. Margin- RSI (14)55.39 Volatility5.27% 6.37%
OptionableYes Debt/Eq0.00 EPS Q/Q-45.10% Profit Margin- Rel Volume0.66 Prev Close36.35
ShortableYes LT Debt/Eq0.00 EarningsMay 11 AMC Payout- Avg Volume1.07M Price35.26
Recom1.70 SMA204.07% SMA5011.60% SMA20048.07% Volume710,148 Change-3.00%
May-13-20Initiated H.C. Wainwright Buy $42
Mar-04-20Initiated Barclays Overweight $40
Jan-09-20Downgrade BMO Capital Markets Outperform → Market Perform $22
Dec-30-19Reiterated Mizuho Buy $27 → $33
Dec-09-19Upgrade Wells Fargo Market Perform → Outperform
Nov-12-19Initiated SunTrust Buy $25
Nov-06-19Downgrade Wells Fargo Outperform → Market Perform
Oct-01-19Initiated Stifel Buy $27
Aug-09-19Initiated BTIG Research Buy $27
Jul-22-19Initiated Cantor Fitzgerald Overweight
Jul-12-19Initiated Oppenheimer Outperform $27
Jun-13-19Initiated Mizuho Buy
Jun-07-19Initiated ROTH Capital Neutral $20
May-31-19Initiated Guggenheim Buy
May-24-19Resumed Citigroup Buy $26
Mar-28-19Initiated SVB Leerink Outperform $20
Jan-03-19Downgrade Stephens Overweight → Equal-Weight
Nov-05-18Initiated Jefferies Buy
Aug-01-18Initiated Citigroup Buy $20
Mar-06-18Downgrade H.C. Wainwright Buy → Neutral $12
Jul-10-20 10:18AM  
Jul-09-20 08:00AM  
Jun-15-20 10:50PM  
01:44PM  
Jun-13-20 07:50AM  
Jun-11-20 04:01PM  
Jun-09-20 05:29PM  
02:10PM  
12:49AM  
Jun-08-20 04:01PM  
May-20-20 08:00AM  
May-15-20 06:18AM  
May-12-20 04:30PM  
01:40PM  
May-11-20 05:15PM  
04:01PM  
May-08-20 08:46AM  
May-05-20 09:18PM  
04:01PM  
May-04-20 04:01PM  
09:38AM  
Apr-30-20 08:33AM  
Apr-29-20 07:11AM  
Apr-28-20 04:30PM  
12:33PM  
Apr-14-20 09:13AM  
Apr-10-20 12:00PM  
Apr-08-20 11:30AM  
10:05AM  
10:04AM  
Apr-06-20 09:08AM  
Apr-04-20 09:07AM  
Apr-03-20 06:34PM  
04:20PM  
10:57AM  
07:36AM  
Apr-02-20 04:46PM  
04:45PM  
Mar-25-20 09:04AM  
Mar-17-20 10:24AM  
Mar-02-20 05:15PM  
04:01PM  
Feb-29-20 02:52PM  
Feb-26-20 08:00AM  
Feb-25-20 12:30PM  
Feb-07-20 08:00AM  
Feb-05-20 11:52AM  
Jan-16-20 06:15AM  
Jan-13-20 08:00AM  
Jan-03-20 10:44AM  
Dec-13-19 02:18PM  
Dec-11-19 09:41AM  
Dec-10-19 09:52AM  
09:48AM  
09:07AM  
Dec-09-19 04:19PM  
02:16PM  
11:04AM  
Dec-08-19 07:28PM  
10:39AM  
Dec-07-19 08:40AM  
Dec-02-19 05:49AM  
Nov-27-19 04:01PM  
Nov-14-19 04:01PM  
Nov-06-19 09:01AM  
Nov-05-19 07:25PM  
04:05PM  
Oct-29-19 04:01PM  
Oct-28-19 07:44PM  
Oct-18-19 08:12AM  
05:57AM  
Oct-01-19 01:48PM  
Sep-30-19 08:00AM  
Sep-18-19 04:01PM  
Sep-12-19 07:38AM  
12:53AM  
Sep-11-19 04:01PM  
Sep-10-19 11:06AM  
Sep-04-19 10:02AM  
Sep-03-19 08:01AM  
Aug-29-19 08:00AM  
Aug-14-19 08:00AM  
Aug-09-19 11:50AM  
Aug-07-19 12:20PM  
Aug-06-19 06:35PM  
03:00PM  
Jul-31-19 01:48PM  
Jul-30-19 04:01PM  
Jul-29-19 10:34AM  
Jul-26-19 09:39AM  
Jul-17-19 04:01PM  
Jul-08-19 08:15AM  
Jun-19-19 06:02PM  
Jun-05-19 05:06AM  
May-30-19 04:05PM  
May-29-19 08:40AM  
07:24AM  
May-07-19 10:41PM  
06:15PM  
05:07PM  
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development includes FT516 for the treatment of acute myeloid leukemia (AML) and B-cell lymphoma, FT596 to treat B-cell lymphoma and CLL, FT538 to treat AML and multiple myeloma, FT576 to treat multiple myeloma, FT819 to treat B-cell malignancies, and FT-ONO1 to treat hematologic malignancies; and FT500, FT516, and FT-ONO2 for the treatment of advanced solid tumors. The company's NK- and T-cell immuno-oncology programs under development also includes ProTmune for the treatment of hematologic malignancies; FATE-NK100 for the treatment of recurrent ovarian cancer; and FATE-NK100 for the treatment of advanced solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc. Fate Therapeutics, Inc. was founded in 2007 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Redmile Group, LLCDirectorJun 11Buy28.311,412,92839,999,99212,629,737Jun 17 08:25 PM
RASTETTER WILLIAM HDirectorMar 30Option Exercise1.3728,46138,99228,461Mar 31 04:01 PM
Valamehr BahramChief Development OfficerFeb 03Option Exercise1.691,1531,94987,211Feb 04 04:01 PM
Wolchko J ScottPresident and CEOJan 30Option Exercise2.7025,00067,500444,969Feb 03 04:01 PM
Wolchko J ScottPresident and CEOJan 30Sale25.4525,000636,303419,969Feb 03 04:01 PM
Valamehr BahramChief Development OfficerJan 08Sale20.695,700117,94786,058Jan 10 04:03 PM
TAHL CINDYGeneral Counsel and SecretaryJan 08Sale20.725,700118,08599,518Jan 10 04:02 PM
Shoemaker Daniel DChief Scientific OfficerJan 08Sale20.705,700117,986143,091Jan 10 04:01 PM
Shoemaker Daniel DChief Scientific OfficerDec 30Option Exercise2.9025,00072,500148,791Jan 02 04:01 PM
Shoemaker Daniel DChief Scientific OfficerDec 30Sale19.5025,000487,427123,791Jan 02 04:01 PM
Wolchko J ScottPresident and CEODec 20Option Exercise2.7025,00067,500378,969Dec 23 04:02 PM
Wolchko J ScottPresident and CEODec 20Sale20.1725,000504,158353,969Dec 23 04:02 PM
Wolchko J ScottPresident and CEODec 19Option Exercise2.7025,00067,500378,969Dec 23 04:02 PM
Wolchko J ScottPresident and CEODec 19Sale20.0825,000501,898353,969Dec 23 04:02 PM
Valamehr BahramChief Development OfficerOct 15Sale14.186,20087,89166,758Oct 16 04:06 PM
Wolchko J ScottPresident and CEOOct 15Sale14.4421,017303,458353,969Oct 16 04:07 PM
TAHL CINDYGeneral Counsel and SecretaryOct 15Sale14.2410,200145,29280,218Oct 16 04:05 PM
Shoemaker Daniel DChief Scientific OfficerOct 15Sale14.2911,800168,593123,791Oct 16 04:04 PM
Redmile Group, LLCDirectorSep 16Buy17.50857,14315,000,00311,216,809Sep 17 04:22 PM
Nashat AmirDirectorAug 01Sale22.5330,866695,3927,539Aug 02 04:32 PM
Nashat AmirDirectorJul 31Sale22.5331,139701,6747,743Aug 02 04:32 PM
Nashat AmirDirectorJul 30Sale22.5190,1752,029,5607,949Jul 30 06:25 PM
Nashat AmirDirectorJul 29Sale22.503297,4038,545Jul 30 06:25 PM
Nashat AmirDirectorJul 26Sale22.5027,829626,1538,548Jul 30 06:25 PM
Nashat AmirDirectorJul 24Sale22.5119,866447,0988,732Jul 25 06:24 PM
Nashat AmirDirectorJul 23Sale22.5162,0331,396,0538,864Jul 25 06:24 PM
Nashat AmirDirectorJul 22Sale22.5248,7041,097,0199,275Jul 22 05:52 PM
Nashat AmirDirectorJul 19Sale22.501,05323,6939,598Jul 22 05:52 PM
Nashat AmirDirectorJul 18Sale22.5021,409481,7959,605Jul 22 05:52 PM